Ghost Tree Capital’s Sage Therapeutics SAGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-30,000
Closed -$2.25M 66
2021
Q1
$2.25M Buy
+30,000
New +$2.46M 0.53% 42
2020
Q2
Sell
-65,000
Closed -$1.87M 50
2020
Q1
$1.87M Buy
+65,000
New +$3.76M 0.5% 37
2019
Q4
Sell
-110,000
Closed -$13.5M 57
2019
Q3
$15.4M Buy
110,000
+80,000
+267% +$13.4M 3.93% 7
2019
Q2
$5.49M Sell
30,000
-45,000
-60% -$7.68M 1.14% 27
2019
Q1
$11.9M Buy
75,000
+71,700
+2,173% +$10.4M 3.12% 10
2018
Q4
$316K Sell
3,300
-6,200
-65% -$710K 0.11% 38
2018
Q3
$1.34M Buy
+9,500
New +$1.47M 0.29% 47
2018
Q2
Sell
-11,100
Closed -$1.79M 55
2018
Q1
$1.79M Sell
11,100
-10,437
-48% -$1.77M 0.36% 47
2017
Q4
$3.55M Buy
+21,537
New +$2.09M 0.83% 35
2017
Q3
Sell
-50,000
Closed -$3.93M 72
2017
Q2
$3.98M Sell
50,000
-50,000
-50% -$3.61M 0.83% 46
2017
Q1
$7.11M Sell
100,000
-100,000
-50% -$5.86M 1.32% 34
2016
Q4
$10.2M Buy
200,000
+25,000
+14% +$1.18M 2.46% 9
2016
Q3
$8.06M Buy
+175,000
New +$7.12M 1.31% 26
2016
Q2
Sell
-160,000
Closed -$5.34M 78
2016
Q1
$5.13M Sell
160,000
-40,000
-20% -$1.41M 2.9% 14
2015
Q4
$11.7M Buy
200,000
+159,200
+390% +$7.89M 4.77% 5
2015
Q3
$1.73M Sell
40,800
-16,700
-29% -$1.03M 0.78% 49
2015
Q2
$4.2M Sell
57,500
-62,500
-52% -$4.02M 1.36% 34
2015
Q1
$6.03M Buy
+120,000
New +$5.16M 2.17% 12

Other funds holding SAGE

Ghost Tree Capital's SAGE Position: Q2 2021 in Review

Ghost Tree Capital sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 30,000 shares — an estimated $2.25M sold.

Ghost Tree Capital first reported a position in SAGE in Q1 2015 and held it in 18 quarters. The position peaked at $15.4M in Q3 2019. 256 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Ghost Tree Capital reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ghost Tree Capital sold 30,000 Sage Therapeutics shares in Q2 2021, an estimated $2.25M.
  • Ghost Tree Capital first reported a position in Sage Therapeutics in Q1 2015 and held it in 18 quarters.
  • Ghost Tree Capital's Sage Therapeutics position peaked at $15.4M in Q3 2019.
  • 256 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Ghost Tree Capital's 13F filing for Q2 2021, filed 11 Aug 2021.